Telomeres and telomerase in chronic myeloid leukaemia: Impact for pathogenesis, disease progression and targeted therapy

Hematological Oncology

Volumn 27, Issue 3, 2009, Pages 123-129

  Keller, Gunhild ^a   Brassat, Ute ^a   Braig, Melanie ^a   Heim, Denise ^a   Wege, Henning ^a   Brümmendorf, Tim H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bcr Abl; Blast crisis; Chronic myeloid leukaemia; Telomerase; Telomere

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; BIBR 1532; BLEOMYCIN; DOXORUBICIN; ETOPOSIDE; GRN 163L; HYDROXYUREA; IMATINIB; MESSENGER RNA; SMALL INTERFERING RNA; TANKYRASE; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; GENOMIC INSTABILITY; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; HUMAN; LEUKEMOGENESIS; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TELOMERE;

ANIMALS; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; TELOMERASE; TELOMERE;

EID: 70350708508     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.901     Document Type: Review

References (67)

1. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97(4): 503-514.
2. Blackburn EH. Telomere states and cell fates. Nature 2000; 408(6808): 53-56.
3. Fajkus J, Simickova M, Malaska J. Tiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology. Philos Trans R Soc Lond B Biol Sci 2002; 357(1420): 545-562.
4. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19(18): 2100-2110.
5. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345(6274): 458-460.
6. Harley CB, Vaziri H, Counter CM, Allsopp RC. The telomere hypothesis of cellular aging. Exp Gerontol 1992; 27(4): 375-382.
7. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008; 8(6): 450-458.
8. Forsyth NR, Wright WE, Shay JW. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation 2002; 69(4-5): 188-197.
9. Collins K. Mammalian telomeres and telomerase. Curr Opin Cell Biol 2000; 12(3): 378-383.
10. Kakuo S, Asaoka K, Ide T. Human is a unique species among primates in terms of telomere length. Biochem Biophys Res Commun 1999; 263(2): 308-314.
11. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001; 97(4): 895-900.
12. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000; 95(6): 1883-1890.
13. Boultwood J, Fidler C, Kusec R, et al. Telomere length in myelodysplastic syndromes. Am J Hematol 1997; 56(4): 266-271.
14. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91(1): 25-34.
15. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, Greider CW 2nd DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392(6676): 569-574.
16. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995; 269(5228): 1236-1241.
17. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277(5328): 955-959.
18. Harrington JJ, Van Bokkelen G, Mays RW, Gustashaw K, Willard HF. Formation of de novo centromeres and construction of firstgeneration human artificial microchromosomes. Nat Genet 1997; 15(4): 345-355.
19. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002; 21(4): 541-552.
20. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007; 96(7): 1020-1024.
21. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33(5): 787-791.
22. Weng NP, Hathcock KS, Hodes RJ. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity 1998; 9(2): 151-157.
23. De Lange T. Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 197-204.
24. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003; 40 (suppl. 2):4-10.
25. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91(21): 9857-9860.
26. Drummond M, Lennard A, Brummendorf T, Holyoake T. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk Lymphoma 2004; 45(9): 1775-1781.
27. Boultwood J, Fidler C, Shepherd P, et al. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol 1999; 61(1): 5-9.
28. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia 1997; 11(2): 190-194.
29. Ohyashiki K, Iwama H, Tauchi T, et al. Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia. Leuk Lymphoma 2000; 40(1-2): 49-56.
30. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92(20): 9082-9086.
31. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K, Telomeres and, telomerase in hematologic neoplasia. Oncogene 2002; 21(4): 680-687.
32. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 2000; 60(3): 610-617.
33. Passos JF, Saretzki G, von Zglinicki T. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? Nucleic Acids Res 2007; 35(22): 7505-7513.
34. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002; 27(7): 339-344.
35. Drummond MW, Hoare SF, Monaghan A, et al. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia 2005; 19(3): 381-389.
36. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 1997; 90(1): 182-193.
37. Holt SE, Aisner DL, Shay JW, Wright WE. Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci USA 1997; 94(20): 10687-10692.
38. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 1997; 94(25): 13677-13682.
39. Iwama H, Ohyashiki K, Ohyashiki JH, et al. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia. Cancer 1997; 79(8): 1552-1560.
40. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105(7): 2640-2653.
41. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2003; 348(11): 994-1004.
42. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349(15): 1423-1432.
43. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYNkinaseoverexpression inchronicmyelogenousleukemiacells selected for resistance to STI571. Blood 2003; 101(2): 690-698.
44. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530-3539.
45. Brummendorf TH, Ersoz I, Hartmann U, et al. Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. Blood 2003; 101(1): 375-376.
46. Hartmann U, Balabanov S, Ziegler P, et al. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. Exp Hematol 2005; 33(5): 542-549.
47. Bodoni et al. ASH 2008 Abstract #3183.
48. Campbell LJ, Fidler C, Eagleton H, et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006; 20(4): 671-679.
49. Kharbanda S, Kumar V, Dhar S, et al. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol 2000; 10(10): 568-575.
50. Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Shinohara Y, Baba Y. Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem Pharmacol 2003; 66; (10): 1879-1884.
51. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8(3): 167-179.
52. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5(10): 1164-1170.
53. Cerone MA, Londono-Vallejo JA, Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther 2006; 5(7): 1669-1675.
54. Roth A, Vercauteren S, Sutherland HJ, Lansdorp PM. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 2003; 17(12): 2410-2417.
55. Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 2005; 68(3): 779-786.
56. Damm K, Hemmann U, Garin-Chesa P, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. Embo J 2001; 20(24): 6958-6968.
57. Parsch D, Brassat U, Brummendorf TH, Fellenberg J. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest 2008; 26(6): 590-596.
58. Brassat UBS, Hartmann U, Bali D, Borgmann K, Dierlamm D, Brümmendorf TH. Comparative analysis of pharmacological and non-pharmacilogical telomerase inhibition in BCR-ABL-positive CML cells. Blood ASH Annual Meeting Abstracts 2007; Abstract #2935.
59. Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3'->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005; 24(33): 5262-5268.
60. Gomez-Millan J, Goldblatt EM, Gryaznov SM, Mendonca MS, Herbert BS. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Int J Radiat Oncol Biol Phys 2007; 67(3): 897-905.
61. de Souza Nascimento P, Alves G, Fiedler W. Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells. Oncol Rep 2006; 16(2): 423-428.
62. Falchetti ML, Fiorenzo P, Mongiardi MP, et al. Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurol Res 2006; 28(5): 532-537.
63. Nakamura M, Masutomi K, Kyo S, et al. Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 2005; 16(7): 859-868.
64. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998; 16(25): 3323-3330.
65. Kondo Y, Koga S, Komata T, Kondo S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 2000; 19(18): 2205-2211.
66. Kushner DM, Paranjape JM, Bandyopadhyay B, et al. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 2000; 76(2): 183-192.
67. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001; 19(3): 114-120.